Insider transactions

EDGAR

CULLINAN THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
29 transactions, 169,912 shares
Sum of shares × price per share: 2,558,835.7

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 60

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-05 Filed 2026-11-06Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,8054.30
16,361.5

Derived: shares × price per share. Exact value 16361.50.

162,649Direct (D) Yes— Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,00012.36
49,440

Derived: shares × price per share. Exact value 49440.00.

158,649Direct (D) Yes
F1
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,805) — exercise price 4.30
Disposed (D)3,8050—75,182Direct (D) Yes
F2
  • F2 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-452004 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-10Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0004.30
17,200

Derived: shares × price per share. Exact value 17200.00.

166,844Direct (D) Yes— Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-10Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,00021.57
172,560

Derived: shares × price per share. Exact value 172560.00.

158,844Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-10Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 4.30
Disposed (D)4,0000—78,987Direct (D) Yes
F3
  • F3 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-387381 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)30,0004.30
129,000

Derived: shares × price per share. Exact value 129000.00.

192,844Direct (D) Yes— Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30,00020.26
607,800

Derived: shares × price per share. Exact value 607800.00.

162,844Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row
2026-08-13 Filed 2026-08-14Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (30,000) — exercise price 4.30
Disposed (D)30,0000—82,987Direct (D) Yes
F3
  • F3 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-352523 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0004.30
17,200

Derived: shares × price per share. Exact value 17200.00.

170,844Direct (D) Yes— Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,00017.82
142,560

Derived: shares × price per share. Exact value 142560.00.

162,844Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.35 to $18.19. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 4.30
Disposed (D)4,0000—112,987Direct (D) Yes
F3
  • F3 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-297605 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02SUMER JACQUELYN L Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,4708.60
21,242

Derived: shares × price per share. Exact value 21242.00.

130,559Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the ESPP), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026.
Open filing 0001193125-26-294869 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Fenton Mary Kay Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,5418.60
13,252.6

Derived: shares × price per share. Exact value 13252.60.

127,921Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the ESPP), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026.
Open filing 0001193125-26-294863 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Rosenberg Anthony Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (25,319) — exercise price 13.55
Acquired (A)25,3190—25,319Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276060 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Doyle Mittie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,781) — exercise price 13.55
Acquired (A)21,7810—21,781Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276054 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Meek David D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (25,319) — exercise price 13.55
Acquired (A)25,3190—25,319Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276059 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Allen Andrew R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,781) — exercise price 13.55
Acquired (A)21,7810—21,781Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276056 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Webster Stephen W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (25,319) — exercise price 13.55
Acquired (A)25,3190—25,319Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276057 Read from the filing’s XML Dispute this row
2026-06-16 Filed 2026-06-18Thistle Mary Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (25,319) — exercise price 13.55
Acquired (A)25,3190—25,319Direct (D) No
F1
  • F1 The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Open filing 0001193125-26-276055 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0004.30
17,200

Derived: shares × price per share. Exact value 17200.00.

174,844Direct (D) Yes— Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,80014.60
113,880

Derived: shares × price per share. Exact value 113880.00.

167,044Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.12. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20015.58
3,116

Derived: shares × price per share. Exact value 3116.00.

166,844Direct (D) Yes
F1, F3
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.56 to $15.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-06Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 4.30
Disposed (D)4,0000—116,987Direct (D) Yes
F4
  • F4 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-209307 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-09Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0004.30
17,200

Derived: shares × price per share. Exact value 17200.00.

178,844Direct (D) Yes— Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-09Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,00015.68
125,440

Derived: shares × price per share. Exact value 125440.00.

170,844Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.38 to $16.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-09Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 4.30
Disposed (D)4,0000—120,987Direct (D) Yes
F3
  • F3 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-098781 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-26Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,78014.14
25,169.2

Derived: shares × price per share. Exact value 25169.20.

174,844Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.89 to $14.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-077259 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-25Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,60114.47
52,106.47

Derived: shares × price per share. Exact value 52106.47.

176,624Direct (D) Yes
F3
  • F3 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-072002 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-25SUMER JACQUELYN L Officer: Chief Legal Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,60114.47
52,106.47

Derived: shares × price per share. Exact value 52106.47.

128,089Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-071997 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-25Jones Jeffrey Alan Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,58214.47
66,301.54

Derived: shares × price per share. Exact value 66301.54.

159,968Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-072000 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-02-25AHMED NADIM Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13,51514.47
195,562.05

Derived: shares × price per share. Exact value 195562.05.

390,803Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-072001 Read from the filing’s XML Dispute this row
2026-02-23 Filed 2026-02-25Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,75213.99
24,510.48

Derived: shares × price per share. Exact value 24510.48.

180,225Direct (D) Yes
F1, F2
  • F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.68 to $14.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-072002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Jones Jeffrey Alan Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,98213.62
67,854.84

Derived: shares × price per share. Exact value 67854.84.

164,550Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-064257 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Fenton Mary Kay Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,39813.62
59,900.76

Derived: shares × price per share. Exact value 59900.76.

126,380Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-064261 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23SUMER JACQUELYN L Officer: Chief Legal Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,74213.62
50,966.04

Derived: shares × price per share. Exact value 50966.04.

131,690Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-064255 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,74213.62
50,966.04

Derived: shares × price per share. Exact value 50966.04.

181,977Direct (D) Yes
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)8,0004.30
34,400

Derived: shares × price per share. Exact value 34400.00.

189,977Direct (D) Yes— Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,00014.30
114,400

Derived: shares × price per share. Exact value 114400.00.

181,977Direct (D) Yes
F2
  • F2 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23Michaelson Jennifer Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,000) — exercise price 4.3
Disposed (D)8,0000.00
0

Derived: shares × price per share. Exact value 0.00.

124,987Direct (D) Yes
F3
  • F3 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Open filing 0001193125-26-064256 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-23AHMED NADIM Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,38113.62
223,109.22

Derived: shares × price per share. Exact value 223109.22.

404,318Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-064254 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Jones Jeffrey Alan Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 12.44
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059640 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19AHMED NADIM Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (828,000) — exercise price 12.44
Acquired (A)828,0000—828,000Direct (D) No
F1
  • F1 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059639 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Michaelson Jennifer Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)57,5000—185,719Direct (D) No
F1
  • F1 The shares underlying the restricted stock unit vest on an annual basis over four years.
Open filing 0001193125-26-059636 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Michaelson Jennifer Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (115,000) — exercise price 12.44
Acquired (A)115,0000—115,000Direct (D) No
F2
  • F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059636 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Savill Corrine Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (175,000) — exercise price 12.44
Acquired (A)175,0000—175,000Direct (D) No
F1
  • F1 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059638 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Fenton Mary Kay Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)68,7500—130,778Direct (D) No
F1
  • F1 The shares underlying the restricted stock unit vest on an annual basis over four years.
Open filing 0001193125-26-059637 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19Fenton Mary Kay Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (137,500) — exercise price 12.44
Acquired (A)137,5000—137,500Direct (D) No
F2
  • F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059637 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-19SUMER JACQUELYN L Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (230,000) — exercise price 12.44
Acquired (A)230,0000—230,000Direct (D) No
F1
  • F1 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Open filing 0001193125-26-059641 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Michaelson Jennifer Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)41612.03
5,004.48

Derived: shares × price per share. Exact value 5004.48.

128,219Direct (D) No
F1
  • F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Open filing 0001193125-26-051700 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 191

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
MPM BIOIMPACT LLC 9,721,081 SH149,218,593 dollarsLower by 10,260 Prior quarter: 9,731,341Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row
Lynx1 Capital Management LP Partly reported under another manager8,963,500 SH137,589,725 dollarsUnchanged Prior quarter: 8,963,500Open filing 0001910456-26-000007 Filed 2026-11-16 Dispute this row
BVF INC/IL Partly reported under another manager5,750,683 SH88,272,984 dollarsUnchanged Prior quarter: 5,750,683Open filing 0000921895-26-003162 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager5,319,313 SH81,651,455 dollarsHigher by 86,547 Prior quarter: 5,232,766Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager4,091,640 SH62,807 dollarsHigher by 265,690 Prior quarter: 3,825,950Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Kynam Capital Management, LP 3,114,132 SH47,801,926 dollarsUnchanged Prior quarter: 3,114,132Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,641,522 SH40,547,363 dollarsHigher by 27,456 Prior quarter: 2,614,066Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager2,604,105 SH39,973,012 dollarsLower by 1,064,522 Prior quarter: 3,668,627Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
RTW INVESTMENTS, LP 2,364,347 SH36,292,726 dollarsUnchanged Prior quarter: 2,364,347Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row
Siren, L.L.C. Partly reported under another manager1,793,410 SH27,528,844 dollarsLower by 100,000 Prior quarter: 1,893,410Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,448,600 SH22,240,987 dollarsLower by 98,709 Prior quarter: 1,547,309Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Blue Owl Capital Holdings LP Partly reported under another manager1,399,899 SH21,488,450 dollarsLower by 139,865 Prior quarter: 1,539,764Open filing 0001193125-26-459653 Filed 2026-11-13 Dispute this row
Venrock Adviser, LLC 1,379,965 SH21,182,463 dollarsUnchanged Prior quarter: 1,379,965Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,084,765 SH16,650,457 dollarsHigher by 38,071 Prior quarter: 1,046,694Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager988,963 SH15,180,582 dollarsLower by 12,635 Prior quarter: 1,001,598Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Elmind Capital, LP 962,792 SH14,778,857 dollarsHigher by 272,792 Prior quarter: 690,000Open filing 0001013594-26-001197 Filed 2026-11-16 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 953,126 SH14,630,484 dollarsLower by 129,485 Prior quarter: 1,082,611Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
Affinity Asset Advisors, LLC 875,760 SH13,442,916 dollarsUnchanged Prior quarter: 875,760Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
Fisher Asset Management, LLC Partly reported under another manager800,961 SH12,294,750 dollarsHigher by 764,963 Prior quarter: 35,998Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row
BOONE CAPITAL MANAGEMENT LLC 690,814 SH10,603,995 dollarsLower by 13,628 Prior quarter: 704,442Open filing 0001214659-26-014343 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager644,639 SH9,895,209 dollarsHigher by 15,604 Prior quarter: 629,035Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 643,491 SH9,877,587 dollarsLower by 95,250 Prior quarter: 738,741Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
TWIN FOCUS CAPITAL PARTNERS, LLC 595,489 SH9,140,756 dollarsUnchanged Prior quarter: 595,489Open filing 0001172661-26-005036 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager558,159 SH8,567,740 dollarsLower by 12,921 Prior quarter: 571,080Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 506,077 SH7,768,282 dollarsHigher by 42,043 Prior quarter: 464,034Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager498,566 SH7,652,989 dollarsLower by 82,772 Prior quarter: 581,338Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
Boxer Capital Management, LLC 450,000 SH6,907,500 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager415,972 SH6,385,170 dollarsLower by 94,353 Prior quarter: 510,325Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
TCG Crossover Management, LLC 406,786 SH6,244,165 dollarsUnchanged Prior quarter: 406,786Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager377,837 SH5,799,798 dollarsLower by 5,003 Prior quarter: 382,840Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO 376,124 SH5,773,503 dollarsHigher by 12,988 Prior quarter: 363,136Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
FMR LLC Partly reported under another manager336,451 SH5,164,516 dollarsHigher by 96,336 Prior quarter: 240,115Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
GREAT POINT PARTNERS LLC Partly reported under another manager300,000 SH4,605,000 dollarsUnchanged Prior quarter: 300,000Open filing 0001172661-26-005345 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager290,011 SH4,451,669 dollarsLower by 36,800 Prior quarter: 326,811Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 286,096 SH4,391,574 dollarsLower by 6,404 Prior quarter: 292,500Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
Invesco Ltd. Partly reported under another manager283,144 SH4,346,261 dollarsHigher by 139,592 Prior quarter: 143,552Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager273,316 SH4,162,602 dollarsLower by 9,315 Prior quarter: 282,631Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager262,713 SH4,032,645 dollarsHigher by 97,997 Prior quarter: 164,716Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
Bleichroeder LP 250,000 SH3,837,500 dollarsUnchanged Prior quarter: 250,000Open filing 0001420506-26-002662 Filed 2026-11-13 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager240,700 SH3,694,745 dollarsHigher by 204,700 Prior quarter: 36,000Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager236,200 SH3,625,670 dollarsHigher by 149,600 Prior quarter: 86,600Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager229,203 SH3,518,266 dollarsLower by 19,424 Prior quarter: 248,627Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
TWO SIGMA INVESTMENTS, LP 219,719 SH3,372,687 dollarsLower by 52,862 Prior quarter: 272,581Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager217,500 SH3,338,625 dollarsHigher by 180,800 Prior quarter: 36,700Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Trexquant Investment LP Partly reported under another manager209,314 SH3,212,970 dollarsHigher by 57,151 Prior quarter: 152,163Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager201,600 SH3,094,560 dollarsHigher by 136,400 Prior quarter: 65,200Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Apis Capital Advisors, LLC 192,000 SH2,947,200 dollarsHigher by 112,000 Prior quarter: 80,000Open filing 0001420506-26-002720 Filed 2026-11-13 Dispute this row
MOORE CAPITAL MANAGEMENT, LP 181,306 SH2,783,047 dollarsLower by 8,640 Prior quarter: 189,946Open filing 0001448574-26-000004 Filed 2026-11-16 Dispute this row
BARCLAYS PLC Partly reported under another manager177,595 SH2,726,082 dollarsHigher by 33,650 Prior quarter: 143,945Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
HighVista Strategies LLC 173,895 SH2,669,289 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-004983 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Sixth Street Partners Management Company, L.P. 464,034 SH
  • PERCEPTIVE ADVISORS LLC 426,478 SH
  • ADAGE CAPITAL PARTNERS GP, L.L.C. 238,000 SH
  • Assenagon Asset Management S.A. 123,364 SH
  • Y-Intercept (Hong Kong) Ltd 80,648 SH
  • Point72 Asset Management, L.P. 75,009 SH
  • MARSHALL WACE, LLP 66,051 SH
  • Soleus Capital Management, L.P. 50,000 SH
  • ALGERT GLOBAL LLC 36,851 SH
  • Verdad Advisers, LP 28,987 SH
  • ExodusPoint Capital Management, LP 28,537 SH
  • OPTIMIZE FINANCIAL INC. 28,061 SH
  • Sound Capital Solutions LLC 28,061 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 21,218 SH
  • MILLENNIUM MANAGEMENT LLC 20,000 SH
  • Qube Research Technologies Ltd 19,936 SH
  • SG Americas Securities, LLC 19,058 SH
  • Jupiter Topco LLC 18,528 SH
  • TWO SIGMA SECURITIES, LLC 15,220 SH
  • AXQ CAPITAL, LP 14,935 SH
  • INTECH INVESTMENT MANAGEMENT LLC 12,418 SH
  • EntryPoint Capital, LLC 11,556 SH
  • Curated Wealth Partners LLC 10,000 SH
  • Quantbot Technologies LP 2,911 SH
  • Integrated Wealth Concepts LLC 1,349 SH
  • Pacer Advisors, Inc. 1,104 SH
  • Optiver Holding B.V. 140 SH
  • Wealth Enhancement Trust Services, Inc. 79 SH
  • NATIONAL BANK OF CANADA /FI/ 23 SH
  • Basecamp Wealth Advisors LLC 14 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
STATE STREET CORPORATION COMMON STOCK42,604,105.0009/30/2026 Filed 2026-11-10SCHEDULE 13GOpen filing 0000093751-26-000639 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share5.73,711,284.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF I GP LLC Common Stock, par value $0.0001 per share5.73,711,284.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share3.52,269,166.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF II GP LLC Common Stock, par value $0.0001 per share3.52,269,166.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share0.6400,861.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF Partners OS Ltd. Common Stock, par value $0.0001 per share0.6400,861.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share9.25,980,450.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share9.996,491,123.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
BVF INC/IL Common Stock, par value $0.0001 per share9.996,491,123.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
LAMPERT MARK N Common Stock, par value $0.0001 per share9.996,491,123.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0000921895-26-002166 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK6.23,825,95006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000080255-26-000574 Dispute this row
STATE STREET CORPORATION COMMON STOCK63,668,627.0006/30/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0000093751-26-000446 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share5.83,551,482.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF I GP LLC Common Stock, par value $0.0001 per share5.83,551,482.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share3.72,272,849.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF II GP LLC Common Stock, par value $0.0001 per share3.72,272,849.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share0.4224,641.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF Partners OS Ltd. Common Stock, par value $0.0001 per share0.4224,641.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share9.45,824,331.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share9.996,161,469.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
BVF INC/IL Common Stock, par value $0.0001 per share9.996,161,469.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
LAMPERT MARK N Common Stock, par value $0.0001 per share9.996,161,469.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0000921895-26-001387 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-001005 Dispute this row
Kynam Capital Management, LP Common Stock, par value $0.0001 per share5.273,114,13212/31/2025 Filed 2026-03-04SCHEDULE 13GOpen filing 0001907884-26-000005 Dispute this row
Kynam Capital Management GP, LLC Common Stock, par value $0.0001 per share5.273,114,13212/31/2025 Filed 2026-03-04SCHEDULE 13GOpen filing 0001907884-26-000005 Dispute this row
Yue Tang Common Stock, par value $0.0001 per share5.273,114,13212/31/2025 Filed 2026-03-04SCHEDULE 13GOpen filing 0001907884-26-000005 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share5.63,302,376.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF I GP LLC Common Stock, par value $0.0001 per share5.63,302,376.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share3.82,271,662.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF II GP LLC Common Stock, par value $0.0001 per share3.82,271,662.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, par value $0.0001 per share0.4224,641.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF Partners OS Ltd. Common Stock, par value $0.0001 per share0.4224,641.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF GP HOLDINGS LLC Common Stock, par value $0.0001 per share9.45,574,038.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF PARTNERS L P/IL Common Stock, par value $0.0001 per share9.995,918,481.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
BVF INC/IL Common Stock, par value $0.0001 per share9.995,918,481.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
LAMPERT MARK N Common Stock, par value $0.0001 per share9.995,918,481.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0000921895-26-000457 Dispute this row
The Vanguard Group Common Stock5.583,298,50412/31/2025 Filed 2026-01-30SCHEDULE 13GOpen filing 0000102909-26-000065 Dispute this row
Lynx1 Capital Management LP Common Stock, par value $0.0001 per share14.58,549,084.0010/08/2025 Filed 2025-10-10SCHEDULE 13G/AAmendment 1Open filing 0000902664-25-004377 Dispute this row
Weston Nichols Common Stock, par value $0.0001 per share14.58,549,084.0010/08/2025 Filed 2025-10-10SCHEDULE 13G/AAmendment 1Open filing 0000902664-25-004377 Dispute this row
Citadel Advisors LLC Common Stock, par value $0.0001 per share (the "Shares")3.11,841,079.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Citadel Advisors Holdings LP Common Stock, par value $0.0001 per share (the "Shares")3.11,841,079.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Citadel GP LLC Common Stock, par value $0.0001 per share (the "Shares")3.11,841,079.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Citadel Securities LLC Common Stock, par value $0.0001 per share (the "Shares")0.3147,828.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Citadel Securities Group LP Common Stock, par value $0.0001 per share (the "Shares")0.3147,828.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Citadel Securities GP LLC Common Stock, par value $0.0001 per share (the "Shares")0.3147,828.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
Kenneth Griffin Common Stock, par value $0.0001 per share (the "Shares")3.41,988,907.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112463 Dispute this row
LYNX1 CAPITAL MANAGEMENT LP Common Stock, par value $0.0001 per share9.85,766,090.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000902664-25-004966 Dispute this row
WESTON NICHOLS Common Stock, par value $0.0001 per share9.85,766,090.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0000902664-25-004966 Dispute this row
Deerfield Mgmt, L.P. Common Stock4.952,927,013.0009/30/2025 Filed 2025-11-13SCHEDULE 13G/AAmendment 1Open filing 0001193805-25-001585 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,316,298 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,836
2016211,665
2017207,865
2018202,770
2019215,153
2020144,184
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to CULLINAN THERAPEUTICS, INC.